Intest Res > Volume 17(1); 2019 > Article |
|
FINANCIAL SUPPORT
The authors received no financial support for the research, authorship, and/or publication of this article.
AUTHOR CONTRIBUTION
Conceptualization: Endo K, Kakuta Y, and Kinouchi Y. Methodology: Moroi R, Yamamoto K, Endo K, Naito T, and Kuroha M. Formal analysis: Moroi R, Yamamoto K, Onodera M, Kanazawa Y, and Kimura T. Writing-original draft: Moroi R, Yamamoto K, and Endo K. Writing-review and editing: Masamune A and Shimosegawa T. Approval of the final manuscript: All authors.
Clinical factor | No. of patients |
Cumulative retention rate |
Cumulative relapse-free survival |
Cumulative surgery-free survival |
---|---|---|---|---|
P-valuea | P-valuea | P-valuea | ||
Sex | ||||
Male | 125 | 0.0497b | 0.4373 | 0.5842 |
Female | 59 | |||
Age at diagnosis (yr) | ||||
<20 yr | 74 | 0.7545 | 0.8738 | 0.5752 |
≥20 yr | 110 | |||
Disease duration at the start of the biologics (yr) | ||||
<3 yr | 73 | 0.9513 | 0.6801 | 0.4236 |
≥3 yr | 111 | |||
Disease location | ||||
Ileal | 26 | 0.2624 | 0.8271 | 0.2010 |
Ileocolonic | 125 | |||
Colonic | 33 | |||
Disease behavior | ||||
Inflammatory | 85 | 0.1904 | 0.7333 | 0.0510 |
Stricture | 62 | |||
Fistula | 37 | |||
Anal disease | ||||
No | 67 | 0.2823 | 0.8176 | 0.4921 |
Yes | 117 | |||
Previous intestinal resection | ||||
No | 110 | 0.7862 | 0.9922 | 0.1886 |
Yes | 84 | |||
Concomitant elemental diet (kcal/day) | ||||
<900 kcal/day | 154 | 0.0430b | 0.9012 | 0.6003 |
≥900 kcal/day | 27 | |||
Concomitant thiopurine | ||||
No | 151 | 0.1837 | 0.8918 | 0.7960 |
Yes | 33 | |||
CRP levels at the baseline (mg/dL) | ||||
<2.6 mg/dL | 140 | 0.0098b | 0.0837 | 0.2189 |
≥2.6 mg/dL | 39 | |||
Serum albumin levels at the baseline (g/dL) | ||||
<3.5 g/dL | 78 | 0.0274b | 0.0257b | 0.0292b |
≥3.5 g/dL | 101 | |||
Anti-TNF-α antibody | ||||
Infliximab | 144 | 0.6921 | 0.1433 | 0.8637 |
Adalimumab | 40 |
Risk factor | No. of patients |
Withdrawal of the biologics |
Relapse |
Surgery |
|||
---|---|---|---|---|---|---|---|
HR (95% CI) | P-valuea | HR (95% CI) | P-valuea | HR (95% CI) | P-valuea | ||
Sex | |||||||
Male | 125 | 1 | 0.0787 | 1 | 0.7359 | 1 | 0.5631 |
Female | 59 | 1.81 (0.93-3.51) | 1.09 (0.65-1.81) | 1.30 (0.53-3.13) | |||
Age at diagnosis | |||||||
<20 yr | 74 | 1 | 0.5888 | 1.10 (0.69-1.76) | 0.6840 | 1 | 0.5704 |
≥20 yr | 110 | 1.21 (0.62-2.44) | 1 | 1.29 (0.54-3.24) | |||
Disease duration | |||||||
<3 yr | 73 | 1.19 (0.55-2.57) | 0.6541 | 1.02 (0.60-1.73) | 0.9501 | 1 | 0.8994 |
≥3 yr | 111 | 1 | 1 | 1.07 (0.40-3.01) | |||
Disease location | |||||||
Ileal | 26 | 1 | 0.2235 | 1.24 (0.54-2.78) | 0.8546 | 4.57 (0.89-34.50) | 0.1586 |
Ileocolonic | 125 | 2.10 (0.71-8.98) | 1.15 (0.64-2.20) | 3.15 (0.83-20.73) | |||
Colonic | 33 | 1.16 (0.30-5.70) | 1 | 1 | |||
Disease behavior | |||||||
Inflammatory | 85 | 1 | 0.0521 | 1 | 0.6233 | 1 | 0.2251 |
Stricture | 62 | 2.02 (0.81-4.88) | 1.20 (0.63-2.29) | 2.04 (0.59-7.25) | |||
Fistula | 37 | 3.84 (1.30-11.29) | 1.46 (0.67-3.10) | 3.42 (0.85-14.09) | |||
Anal disease | |||||||
No | 67 | 1.43 (0.70-2.86) | 0.3244 | 1.11 (0.67-1.82) | 0.6879 | 1.35 (0.55-3.18) | 0.4999 |
Yes | 117 | 1 | 1 | 1 | |||
Previous intestinal resection | |||||||
No | 100 | 2.20 (0.84-6.00) | 0.1091 | 1.11 (0.48-1.66) | 0.7429 | 1.15 (0.36-3.79) | 0.8161 |
Yes | 84 | 1 | 1 | 1 | |||
Combined elemental diet | |||||||
<900 kcal/day | 154 | 3.15 (1.02-13.89) | 0.0454b | 1 | 0.9297 | 1.14 (0.36-4.52) | 0.8339 |
≥900 kcal/day | 27 | 1 | 1.03 (0.60-2.07) | 1 | |||
Combined thiopurine | |||||||
No | 151 | 1 | 0.1921 | 1 | 0.8787 | 1 | 0.5427 |
Yes | 33 | 1.66 (0.76-3.39) | 1.05 (0.57-1.80) | 1.37 (0.47-3.57) | |||
CRP level | |||||||
<2.6 mg/dL | 140 | 1 | 0.0804 | 1 | 0.1564 | 1 | 0.1618 |
≥2.6 mg/dL | 39 | 1.97 (0.92-4.16) | 1.50 (0.85-2.58) | 2.04 (0.74-5.27) | |||
Serum albumin level | |||||||
<3.5 g/dL | 78 | 1.24 (0.63-2.43) | 0.5377 | 1 | 0.0832 | 1.88 (0.78-4.57) | 0.1566 |
≥3.5 g/dL | 101 | 1 | 1.50 (0.95-2.37) | 1 | |||
Anti-TNF-α antibody | |||||||
Infliximab | 144 | 1.47 (0.62-4.08) | 0.3948 | 1.78 (0.91-3.82) | 0.0924 | 1 | 0.9719 |
Adalimumab | 40 | 1 | 1 | 1.02 (0.27-3.02) |